Transiting high dose cytarabine consolidation (HiDAC) chemotherapy to outpatient model of care for Acute Myeloid Leukaemia (AML) patients
Care Continuum
Care Process & Redesign
National University Health System Quality Improvement
National University Health System
31 December 2020
Reduce inpatient length of stay and improve patient experience undergoing HiDAC chemotherapy for AML. HiDAC chemotherapy outpatient care is feasible, safe, and well-received, with cost and hospital efficiency benefits.
Year Submitted: 2020
Published Date: 31 December 2020
Tags: Care Process ＆ Redesign, Care Continuum, Quality Improvement, Workflow Redesign, Access To Care, Bed Occupancy Rate, Value Based Care, Length Of Stay, Patient Reported Experience Measures, Outpatient Care
About this Content
Aims
Reduce inpatient length of stay and improve patient experience undergoing HiDAC chemotherapy for AML.
Background
HiDAC chemotherapy was traditionally inpatient due to 12-hourly infusions; patients desired outpatient care to reduce cost and isolation.
Methods
Literature review, baseline safety data collection, eligibility criteria, pharmacy collaboration, safety network creation, and workflow refinement.
Results
186 bed-days saved, 89% (31/35) HiDAC cycles successful as outpatient; reduced chemotherapy delay from 50 to 18 minutes.
Conclusion
HiDAC chemotherapy outpatient care is feasible, safe, and well-received, with cost and hospital efficiency benefits.
Lessons Learnt
Study root causes, teamwork, engage stakeholders, and communicate changes during pilot phases to ensure success.
Additional Information
Nil conflicts of interest declared.
Keywords
Care Redesign, Quality Improvement, HiDAC, Chemotherapy, Acute Myeloid Leukaemia, Bed-Days Saving, Outpatient Care
Innovators' Details
Innovators' Details
Healthcare Cluster(s) | National University Health System |
Organization(s) Involved | University Cancer Institute Singapore |
Platform(s) | National University Health System Quality Improvement |
Healthcare Professional Group(s) | Medical, Ancillary Care |
Applicable Specialty or Discipline | Oncology |
Project Lead(s) | Chen XiaoJuan |
Project Member(s) | Ng Chin Hin |
Connect with this contributor!
Chen XiaoJuan - xiaojuan_chen@nuhs.edu.sg
Project Attachment
92_NCIS_NUH_QI_2020_Transiting_high_dose_cytarabine_consolidation_HiDAC_chemotherapy_combine.pdf